This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Neurocrine Biosciences, Inc.
Drug Names(s): NBI-6024
Description: NBI-6024 is an altered peptide ligand (APL). APLs have the potential to change the response of T cells that mediate immunity or autoimmunity. In this case, NBI-6024 inhibits the activation of T cells that are reacting to antigens in the pancreas. In theory, this prevents the autoimmune mediated destruction of the pancreatic beta cells seen in type I diabetes.
Partners: Taisho Pharmaceutical Co., Ltd.
Additional information available to subscribers only: